EASL Clinical Practice Guidelines: Liver transplantation

Journal of Hepatology

Volumn 64, Issue 2, 2016, Pages 433-485

  Burra, Patrizia ^b   Burroughs, Andrew ^b   Graziadei, Ivo ^b   Pirenne, Jacques ^b   Valdecasas, Juan Carlos ^b   Muiesan, Paolo ^b   Samuel, Didier ^b   Forns, Xavier ^b  

^a EASL Office   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADDICTION; AGE; ALCOHOL LIVER DISEASE; ARTICLE; AUTOIMMUNE HEPATITIS; BACTERIAL INFECTION; BILE DUCT CARCINOMA; BILE DUCT INJURY; BILIARY TRACT DISEASE; BONE DISEASE; BRAIN DEATH; CANCER SCREENING; CARDIOVASCULAR FUNCTION; CHOLANGITIS; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; EMPLOYMENT; END STAGE LIVER DISEASE; FAMILIAL AMYLOID POLYNEUROPATHY; FOLLOW UP; GRAFT SURVIVAL; HEART DEATH; HEPATITIS B; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFORMED CONSENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LAW; LIFESTYLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; LIVER METASTASIS; LIVER TRANSPLANTATION; LIVING DONOR; MEDICAL SOCIETY; MENTAL DISEASE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MULTICENTER STUDY (TOPIC); MYCOSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITIONAL ASSESSMENT; ORGAN DONOR; OXALOSIS 1; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREGNANCY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RESPIRATORY FUNCTION; RETRANSPLANTATION; RISK ASSESSMENT; SEXUAL FUNCTION; TREATMENT INDICATION; VASCULAR DISEASE; VEIN DISEASE; VIRUS INFECTION; WILSON DISEASE; CONTRAINDICATIONS; EUROPE; PATIENT SELECTION; PROCEDURES; PROGNOSIS;

END STAGE LIVER DISEASE; EUROPE; HUMANS; LIVER TRANSPLANTATION; PATIENT SELECTION; PROGNOSIS; RISK ADJUSTMENT;

EID: 84954380926     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.10.006     Document Type: Article

References (513)

1. R.Y. Calne, R. Williams, J.L. Dawson, I.D. Ansell, D.B. Evans, P.T. Flute, and et al. Liver transplantation in man. II. A report of two orthotopic liver transplants in adult recipients Br Med J 4 1968 541 546
2. T.E. Starzl, T.L. Marchioro, K.A. Porter, and L. Brettschneider Homotransplantation of the liver Transplantation. 5 1967 790 803
3. R. Adam, V. Karam, V. Delvart, J. O'Grady, D. Mirza, J. Klempnauer, and et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR) J Hepatol 57 2012 675 688
4. P. Dutkowski, O. De Rougemont, B. Mullhaupt, and P.A. Clavien Current and future trends in liver transplantation in Europe Gastroenterology 138 2010 802 809 e1-e4
5. P. Dutkowski, M. Linecker, M.L. DeOliveira, B. Mullhaupt, and P.A. Clavien Challenges to liver transplantation and strategies to improve outcomes Gastroenterology 148 2015 307 323
6. G.H. Guyatt, A.D. Oxman, G.E. Vist, R. Kunz, Y. Falck-Ytter, P. Alonso-Coello, and et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BMJ 336 2008 924 926
7. W.M. Lee, R.H. Squires Jr., S.L. Nyberg, E. Doo, and J.H. Hoofnagle Acute liver failure: summary of a workshop Hepatology 47 2008 1401 1415
8. W. Bernal Changing patterns of causation and the use of transplantation in the United kingdom Semin Liver Dis 23 2003 227 237
9. R. Wiesner, E. Edwards, R. Freeman, A. Harper, R. Kim, P. Kamath, and et al. Model for end-stage liver disease (MELD) and allocation of donor livers Gastroenterology 124 2003 91 96
10. M. Malinchoc, P.S. Kamath, F.D. Gordon, C.J. Peine, J. Rank, and P.C. ter Borg A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts Hepatology 31 2000 864 871
11. R.M. Merion, D.E. Schaubel, D.M. Dykstra, R.B. Freeman, F.K. Port, and R.A. Wolfe The survival benefit of liver transplantation Am J Transplant 5 2005 307 313
12. S. Habib, B. Berk, C.C. Chang, A.J. Demetris, P. Fontes, I. Dvorchik, and et al. MELD and prediction of post-liver transplantation survival Liver Transpl 12 2006 440 447
13. R.B. Freeman Jr., R.G. Gish, A. Harper, G.L. Davis, J. Vierling, L. Lieblein, and et al. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula Liver Transpl 12 2006 S128 S136
14. W.R. Kim, S.W. Biggins, W.K. Kremers, R.H. Wiesner, P.S. Kamath, J.T. Benson, and et al. Hyponatremia and mortality among patients on the liver-transplant waiting list N Engl J Med 359 2008 1018 1026
15. T.I. Huo, J.C. Wu, H.C. Lin, F.Y. Lee, M.C. Hou, P.C. Lee, and et al. Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score J Hepatol 42 2005 826 832
16. R.M. Merion, R.A. Wolfe, D.M. Dykstra, A.B. Leichtman, B. Gillespie, and P.J. Held Longitudinal assessment of mortality risk among candidates for liver transplantation Liver Transpl 9 2003 12 18
17. EASL Clinical Practice Guidelines Management of chronic hepatitis B J Hepatol 50 2009 227 242
18. P. Burra, G. Germani, R. Adam, V. Karam, A. Marzano, P. Lampertico, and et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes J Hepatol 58 2013 287 296
19. E. Schiff, C.L. Lai, S. Hadziyannis, P. Neuhaus, N. Terrault, M. Colombo, and et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results Liver Transpl 13 2007 349 360
20. Y.F. Liaw, M. Raptopoulou-Gigi, H. Cheinquer, S.K. Sarin, T. Tanwandee, N. Leung, and et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study Hepatology 54 2011 91 100
21. Y.F. Liaw, I.S. Sheen, C.M. Lee, U.S. Akarca, G.V. Papatheodoridis, F. Suet-Hing Wong, and et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease Hepatology 53 2011 62 72
22. J.H. Shim, H.C. Lee, K.M. Kim, Y.S. Lim, Y.H. Chung, Y.S. Lee, and et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis J Hepatol 52 2010 176 182
23. C.M. Lange, J. Bojunga, W.P. Hofmann, K. Wunder, U. Mihm, S. Zeuzem, and et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function Hepatology 50 2009 2001 2006
24. D. Kapoor, R.C. Guptan, S.M. Wakil, S.N. Kazim, R. Kaul, S.R. Agarwal, and et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis J Hepatol 33 2000 308 312
25. H.L. Tillmann, J. Hadem, L. Leifeld, K. Zachou, A. Canbay, C. Eisenbach, and et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience J Viral Hepat 13 2006 256 263
26. B. Roche, and D. Samuel Liver transplantation in delta virus infection Semin Liver Dis 32 2012 245 255
27. M. Berenguer Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin J Hepatol 49 2008 274 287
28. G. Crespo, Z. Marino, M. Navasa, and X. Forns Viral hepatitis in liver transplantation Gastroenterology 142 2012 1373 1383 e1
29. J.M. Pawlotsky New hepatitis C therapies: the toolbox, strategies, and challenges Gastroenterology 146 2014 1176 1192
30. M. Charlton, G.T. Everson, S.L. Flamm, P. Kumar, C. Landis, R.S. Brown Jr., and et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced disease Gastroenterology 149 2015 649 659
31. J.A. Carrion, E. Martinez-Bauer, G. Crespo, S. Ramirez, S. Perez-del-Pulgar, J.C. Garcia-Valdecasas, and et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study J Hepatol 50 2009 719 728
32. G.T. Everson, N.A. Terrault, A.S. Lok, R. Rodrigo del, R.S. Brown Jr., S. Saab, and et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation Hepatology 57 2013 1752 1762
33. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, S. Roberts, and et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
34. C. Hezode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim, V. Canva, and et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J Hepatol 59 2013 434 441
35. M. Gambato, S. Lens, M. Navasa, and X. Forns Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation J Hepatol 61 2014 S120 S131
36. M.P. Curry, X. Forns, R.T. Chung, N. Terrault, R.S. Brown, J.M. Fenkel, and et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study Gastroenterology 148 2015 100 107
37. F. Poordad, C. Hezode, R. Trinh, K.V. Kowdley, S. Zeuzem, K. Agarwal, and et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1973 1982
38. D.M. Jensen, J.G. O'Leary, P.J. Pockros, K.E. Sherman, P.Y. Kwo, M.E. Mailliard, and et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort Hepatology 60 2014 219A
39. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, I. Jacobson, and et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
40. P. Burra, M. Senzolo, R. Adam, V. Delvart, V. Karam, G. Germani, and et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry) Am J Transplant 10 2010 138 148
41. R. Pfitzmann, J. Schwenzer, N. Rayes, D. Seehofer, R. Neuhaus, and N.C. Nussler Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease Liver Transpl 13 2007 197 205
42. W.R. Yates, M. Martin, D. LaBrecque, D. Hillebrand, M. Voigt, and D. Pfab A model to examine the validity of the 6-month abstinence criterion for liver transplantation Alcohol Clin Exp Res 22 1998 513 517
43. P. Mathurin, V. Duchatelle, M.J. Ramond, C. Degott, P. Bedossa, S. Erlinger, and et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone Gastroenterology 110 1996 1847 1853
44. P. Mathurin, J. O'Grady, R.L. Carithers, M. Phillips, A. Louvet, C.L. Mendenhall, and et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data Gut 60 2011 255 260
45. A. Louvet, S. Naveau, M. Abdelnour, M.J. Ramond, E. Diaz, L. Fartoux, and et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids Hepatology 45 2007 1348 1354
46. R.S. O'Shea, S. Dasarathy, and A.J. McCullough Alcoholic liver disease Hepatology 51 2010 307 328
47. P. Mathurin, C. Moreno, D. Samuel, J. Dumortier, J. Salleron, F. Durand, and et al. Early liver transplantation for severe alcoholic hepatitis N Engl J Med 365 2011 1790 1800
48. M.R. Charlton, J.M. Burns, R.A. Pedersen, K.D. Watt, J.K. Heimbach, and R.A. Dierkhising Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States Gastroenterology 141 2011 1249 1253
49. M. Charlton Evolving aspects of liver transplantation for nonalcoholic steatohepatitis Curr Opin Organ Transplant 18 2013 251 258
50. A.J. Dare, L.D. Plank, A.R. Phillips, E.J. Gane, B. Harrison, D. Orr, and et al. Additive effect of pretransplant obesity, diabetes, and cardiovascular risk factors on outcomes after liver transplantation Liver Transpl 20 2014 281 290
51. A.R. Hakeem, A.J. Cockbain, S.S. Raza, S.G. Pollard, G.J. Toogood, M.A. Attia, and et al. Increased morbidity in overweight and obese liver transplant recipients: a single-center experience of 1325 patients from the United Kingdom Liver Transpl 19 2013 551 562
52. J.S. Rudic, G. Poropat, M.N. Krstic, G. Bjelakovic, and C. Gluud Bezafibrate for primary biliary cirrhosis Cochrane Database Syst Rev 1 2012 CD009145
53. M. Carbone, and J. Neuberger Liver transplantation in PBC and PSC: indications and disease recurrence Clin Res Hepatol Gastroenterol 35 2011 446 454
54. K.M. Boberg, and G.E. Lind Primary sclerosing cholangitis and malignancy Best Pract Res Clin Gastroenterol 25 2011 753 764
55. B. Ringe, A. Weimann, P. Lamesch, B. Nashan, and R. Pichlmayr Liver transplantation as an option in patients with cholangiocellular and bile duct carcinoma Cancer Treat Res 69 1994 259 275
56. S. Singh, E.V. Loftus Jr., and J.A. Talwalkar Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis Am J Gastroenterol 108 2013 1417 1425
57. M.P. Manns, A.J. Czaja, J.D. Gorham, E.L. Krawitt, G. Mieli-Vergani, D. Vergani, and et al. Diagnosis and management of autoimmune hepatitis Hepatology 51 2010 2193 2213
58. P. Ichai, J.C. Duclos-Vallee, C. Guettier, S.B. Hamida, T. Antonini, V. Delvart, and et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis Liver Transpl 13 2007 996 1003
59. S. Fagiuoli, E. Daina, L. D'Antiga, M. Colledan, and G. Remuzzi Monogenic diseases that can be cured by liver transplantation J Hepatol 59 2013 595 612
60. EASL Clinical Practice Guidelines Wilson's disease J Hepatol 56 2012 671 685
61. C.C. Lui, C.L. Chen, Y.F. Cheng, and T.Y. Lee Recovery of neurological deficits in a case of Wilson's disease after liver transplantation Transplant Proc 30 1998 3324 3325
62. V. Medici, V.G. Mirante, L.R. Fassati, M. Pompili, D. Forti, M. Del Gaudio, and et al. Liver transplantation for Wilson's disease: the burden of neurological and psychiatric disorders Liver Transpl 11 2005 1056 1063
63. C. Niederau, R. Fischer, A. Sonnenberg, W. Stremmel, H.J. Trampisch, and G. Strohmeyer Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis N Engl J Med 313 1985 1256 1262
64. L.W. Powell Hemochromatosis: the impact of early diagnosis and therapy Gastroenterology 110 1996 1304 1307
65. K.V. Kowdley, D.J. Brandhagen, R.G. Gish, N.M. Bass, J. Weinstein, M.L. Schilsky, and et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry Gastroenterology 129 2005 494 503
66. A.E. Bobrowski, and C.B. Langman The primary hyperoxalurias Semin Nephrol 28 2008 152 162
67. R.W. Watts The clinical spectrum of the primary hyperoxalurias and their treatment J Nephrol 11 1998 4 7
68. P. Cochat, S. Fargue, and J. Harambat Primary hyperoxaluria type 1: strategy for organ transplantation Curr Opin Organ Transplant 15 2010 590 593
69. B. Hoppe, B.B. Beck, and D.S. Milliner The primary hyperoxalurias Kidney Int 75 2009 1264 1271
70. T. Yamashita, Y. Ando, S. Okamoto, Y. Misumi, T. Hirahara, M. Ueda, and et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy Neurology 78 2012 637 643
71. G. Herlenius, H.E. Wilczek, M. Larsson, and B.G. Ericzon Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry Transplantation 77 2004 64 71
72. V. Plante-Bordeneuve, and G. Said Familial amyloid polyneuropathy Lancet Neurol 10 2011 1086 1097
73. S. Okamoto, J. Wixner, K. Obayashi, Y. Ando, B.G. Ericzon, S. Friman, and et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients' survival Liver Transpl 15 2009 1229 1235
74. Y. Ohya, S. Okamoto, M. Tasaki, M. Ueda, H. Jono, K. Obayashi, and et al. Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation Surg Today 41 2011 1211 1218
75. S. Gustafsson, E. Ihse, M.Y. Henein, P. Westermark, P. Lindqvist, and O.B. Suhr Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis Transplantation 93 2012 1017 1023
76. D. Adams, C. Lacroix, T. Antonini, P. Lozeron, C. Denier, A.M. Kreib, and et al. Symptomatic and proven de novo amyloid polyneuropathy in familial amyloid polyneuropathy domino liver recipients Amyloid 18 2011 174 177
77. T.M. Antonini, P. Lozeron, C. Lacroix, Z. Mincheva, A. Durrbach, M. Slama, and et al. Reversibility of acquired amyloid polyneuropathy after liver retransplantation Am J Transplant 13 2013 2734 2738
78. V. Mazzaferro, E. Regalia, R. Doci, S. Andreola, A. Pulvirenti, F. Bozzetti, and et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 1996 693 699
79. F.Y. Yao, L. Ferrell, N.M. Bass, J.J. Watson, P. Bacchetti, A. Venook, and et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival Hepatology 33 2001 1394 1403
80. E. Vibert, D. Azoulay, E. Hoti, S. Iacopinelli, D. Samuel, C. Salloum, and et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor Am J Transplant 10 2010 129 137
81. C. Duvoux, F. Roudot-Thoraval, T. Decaens, F. Pessione, H. Badran, T. Piardi, and et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria Gastroenterology 143 2012 986 994 e3; quiz e14-e15
82. P.A. Clavien, M. Lesurtel, P.M. Bossuyt, G.J. Gores, B. Langer, and A. Perrier Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report Lancet Oncol 13 2012 e11 e22
83. T.A. Aloia, R. Adam, D. Samuel, D. Azoulay, and D. Castaing A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation J Gastrointest Surg 11 2007 1328 1332
84. J.M. Llovet, X. Mas, J.J. Aponte, J. Fuster, M. Navasa, E. Christensen, and et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation Gut 50 2002 123 128
85. H. Mergental, and R.J. Porte Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis Transpl Int 23 2010 662 667
86. J. Bridgewater, P.R. Galle, S.A. Khan, J.M. Llovet, J.W. Park, T. Patel, and et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma J Hepatol 60 2014 1268 1289
87. C.B. Rosen, J.K. Heimbach, and G.J. Gores Liver transplantation for cholangiocarcinoma Transpl Int 23 2010 692 697
88. A. Rana, and J.C. Hong Orthotopic liver transplantation in combination with neoadjuvant therapy: a new paradigm in the treatment of unresectable intrahepatic cholangiocarcinoma Curr Opin Gastroenterol 28 2012 258 265
89. S. Darwish Murad, W.R. Kim, D.M. Harnois, D.D. Douglas, J. Burton, L.M. Kulik, and et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers Gastroenterology 143 2012 88 98 e3; quiz e14
90. J.P. Lerut, G. Orlando, R. Adam, M. Schiavo, J. Klempnauer, D. Mirza, and et al. The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry Ann Surg 246 2007 949 957 Discussion 57
91. E. Hoti, and R. Adam Liver transplantation for primary and metastatic liver cancers Transpl Int 21 2008 1107 1117
92. M. Hagness, A. Foss, P.D. Line, T. Scholz, P.F. Jorgensen, B. Fosby, and et al. Liver transplantation for nonresectable liver metastases from colorectal cancer Ann Surg 257 2013 800 806
93. J.F. Aduen, B. Sujay, R.C. Dickson, M.G. Heckman, W.R. Hewitt, W.H. Stapelfeldt, and et al. Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years Mayo Clin Proc 84 2009 973 978
94. T.J. Cross, C.G. Antoniades, P. Muiesan, T. Al-Chalabi, V. Aluvihare, K. Agarwal, and et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival Liver Transpl 13 2007 1382 1388
95. C.E. Garcia, R.F. Garcia, A.D. Mayer, and J. Neuberger Liver transplantation in patients over sixty years of age Transplantation 72 2001 679 684
96. S. Moller, and J.H. Henriksen Cirrhotic cardiomyopathy J Hepatol 53 2010 179 190
97. J. An, J.H. Shim, S.O. Kim, D. Lee, K.M. Kim, Y.S. Lim, and et al. Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study Circulation 130 2014 1353 1362
98. W. Bernal, R. Martin-Mateos, M. Lipcsey, C. Tallis, K. Woodsford, M.J. McPhail, and et al. Aerobic capacity during cardiopulmonary exercise testing and survival with and without liver transplantation for patients with chronic liver disease Liver Transpl 20 2014 54 62
99. C. Wray, J.C. Scovotti, J. Tobis, C.U. Niemann, R. Planinsic, A. Walia, and et al. Liver transplantation outcome in patients with angiographically proven coronary artery disease: a multi-institutional study Am J Transplant 13 2013 184 191
100. N. Umeda, and P.S. Kamath Hepatopulmonary syndrome and portopulmonary hypertension Hepatol Res 39 2009 1020 1022
101. D.G. Koch, and M.B. Fallon Hepatopulmonary syndrome Curr Opin Gastroenterol 30 2014 260 264
102. M.R. Arguedas, G.A. Abrams, M.J. Krowka, and M.B. Fallon Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation Hepatology 37 2003 192 197
103. C.M. Pastor, and E. Schiffer Therapy Insight: hepatopulmonary syndrome and orthotopic liver transplantation Nat Clin Pract Gastroenterol Hepatol 4 2007 614 621
104. M. Ashfaq, S. Chinnakotla, L. Rogers, K. Ausloos, S. Saadeh, G.B. Klintmalm, and et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation Am J Transplant 7 2007 1258 1264
105. K.L. Swanson, R.H. Wiesner, S.L. Nyberg, C.B. Rosen, and M.J. Krowka Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups Am J Transplant 8 2008 2445 2453
106. M.M. Hoeper, M.J. Krowka, and C.P. Strassburg Portopulmonary hypertension and hepatopulmonary syndrome Lancet 363 2004 1461 1468
107. O.K. Fix, N.M. Bass, T. De Marco, and R.B. Merriman Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol Liver Transpl 13 2007 875 885
108. G. Fede, G. D'Amico, V. Arvaniti, E. Tsochatzis, G. Germani, D. Georgiadis, and et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis J Hepatol 56 2012 810 818
109. F. Wong, M.K. Nadim, J.A. Kellum, F. Salerno, R. Bellomo, A. Gerbes, and et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis Gut 60 2011 702 709
110. C. Francoz, D. Glotz, R. Moreau, and F. Durand The evaluation of renal function and disease in patients with cirrhosis J Hepatol 52 2010 605 613
111. J.D. Eason, T.A. Gonwa, C.L. Davis, R.S. Sung, D. Gerber, and R.D. Bloom Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK) Am J Transplant 8 2008 2243 2251
112. R.J. Cruz Jr., M.A. Dew, L. Myaskovsky, B. Goodpaster, K. Fox, P. Fontes, and et al. Objective radiologic assessment of body composition in patients with end-stage liver disease: going beyond the BMI Transplantation 95 2013 617 622
113. A.A. Dick, A.L. Spitzer, C.F. Seifert, A. Deckert, R.L. Carithers Jr., J.D. Reyes, and et al. Liver transplantation at the extremes of the body mass index Liver Transpl 15 2009 968 977
114. F. Durand, S. Buyse, C. Francoz, C. Laouenan, O. Bruno, J. Belghiti, and et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography J Hepatol 60 2014 1151 1157
115. G. Langer, K. Grossmann, S. Fleischer, A. Berg, D. Grothues, A. Wienke, and et al. Nutritional interventions for liver-transplanted patients Cochrane Database Syst Rev 8 2012 CD007605
116. L.G. Ferreira, L.R. Anastacio, and M.I. Correia The impact of nutrition on cirrhotic patients awaiting liver transplantation Curr Opin Clin Nutr Metab Care 13 2010 554 561
117. C. Wibaux, I. Legroux-Gerot, S. Dharancy, E. Boleslawski, N. Declerck, V. Canva, and et al. Assessing bone status in patients awaiting liver transplantation Joint Bone Spine 78 2011 387 391
118. A. Alcalde Vargas, J.M. Pascasio Acevedo, I. Gutierrez Domingo, R. Garcia Jimenez, J.M. Sousa Martin, M.T. Ferrer Rios, and et al. Prevalence and characteristics of bone disease in cirrhotic patients under evaluation for liver transplantation Transplant Proc 44 2012 1496 1498
119. J.G. O'Leary, A.J. Demetris, L.S. Friedman, H.M. Gebel, P.F. Halloran, A.D. Kirk, and et al. The role of donor-specific HLA alloantibodies in liver transplantation Am J Transplant 14 2014 779 787
120. T. Gustot, F. Durand, D. Lebrec, J.L. Vincent, and R. Moreau Severe sepsis in cirrhosis Hepatology 50 2009 2022 2033
121. S. Fagiuoli, A. Colli, R. Bruno, A. Craxi, G.B. Gaeta, P. Grossi, and et al. Management of infections pre- and post-liver transplantation: report of an AISF consensus conference J Hepatol 60 2014 1075 1089
122. B.M. Liu, K.J. Chung, C.H. Chen, C.T. Kung, S.F. Ko, P.P. Liu, and et al. Risk factors for the outcome of cirrhotic patients with soft tissue infections J Clin Gastroenterol 42 2008 312 316
123. M.N. Lin, C.C. Tsai, T.H. Hung, and C.C. Tsai The risk of cellulitis in cirrhotic patients: a nationwide population-based study in taiwan Gut Liver 6 2012 482 485
124. R. Cheruvattath, and V. Balan Infections in Patients With End-stage Liver Disease J Clin Gastroenterol 41 2007 403 411
125. P. Tandon, and G. Garcia-Tsao Bacterial infections, sepsis, and multiorgan failure in cirrhosis Semin Liver Dis 28 2008 26 42
126. W.R. Caly, and E. Strauss A prospective study of bacterial infections in patients with cirrhosis J Hepatol 18 1993 353 358
127. M. Falguera, J. Trujillano, S. Caro, R. Menendez, J. Carratala, A. Ruiz-Gonzalez, and et al. A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia Clin Infect Dis 49 2009 409 416
128. M.S. Niederman, L.A. Mandell, A. Anzueto, J.B. Bass, W.A. Broughton, G.D. Campbell, and et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention Am J Respir Crit Care Med 163 2001 1730 1754
129. P. Lenz, B. Conrad, T. Kucharzik, E. Hilker, W. Fegeler, H. Ullerich, and et al. Prevalence, associations, and trends of biliary-tract candidiasis: a prospective observational study Gastrointest Endosc 70 2009 480 487
130. H. Kulaksiz, G. Rudolph, P. Kloeters-Plachky, P. Sauer, H. Geiss, and A. Stiehl Biliary candida infections in primary sclerosing cholangitis J Hepatol 45 2006 711 716
131. S.A. Fischer, and R.K. Avery Screening of donor and recipient prior to solid organ transplantation Am J Transplant 9 2009 S7 S18
132. D. Samuel, R. Weber, P. Stock, J.C. Duclos-Vallee, and N. Terrault Are HIV-infected patients candidates for liver transplantation? J Hepatol 48 2008 697 707
133. N.A. Terrault, M.E. Roland, T. Schiano, L. Dove, M.T. Wong, F. Poordad, and et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection Liver Transpl 18 2012 716 726
134. C. Francoz, D. Valla, and F. Durand Portal vein thrombosis, cirrhosis, and liver transplantation J Hepatol 57 2012 203 212
135. 18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma Liver Transpl 21 2015 572 580
136. M.R. Lucey, and R.M. Weinrieb Alcohol and substance abuse Semin Liver Dis 29 2009 66 73
137. M. Jiao, E.D. Greanya, M. Haque, E.M. Yoshida, and J.G. Soos Methadone maintenance therapy in liver transplantation Prog Transplant 20 2010 209 214 Quiz 15
138. R.M. Weinrieb, and M.R. Lucey Treatment of addictive behaviors in liver transplant patients Liver Transpl 13 2007 S79 S82
139. K.L. Coffman The debate about marijuana usage in transplant candidates: recent medical evidence on marijuana health effects Curr Opin Organ Transplant 13 2008 189 195
140. K. Secunda, E.J. Gordon, M.W. Sohn, L.A. Shinkunas, L.C. Kaldjian, M.D. Voigt, and et al. National survey of provider opinions on controversial characteristics of liver transplant candidates Liver Transpl 19 2013 395 403
141. M. Nickels, A. Jain, R. Sharma, M. Orloff, G. Tsoulfas, R. Kashyap, and et al. Polysubstance abuse in liver transplant patients and its impact on survival outcome Exp Clin Transplant 5 2007 680 685
142. J.A. Leithead, J.W. Ferguson, and P.C. Hayes Smoking-related morbidity and mortality following liver transplantation Liver Transpl 14 2008 1159 1164
143. S. Pungpapong, C. Manzarbeitia, J. Ortiz, D.J. Reich, V. Araya, K.D. Rothstein, and et al. Cigarette smoking is associated with an increased incidence of vascular complications after liver transplantation Liver Transpl 8 2002 582 587
144. F. van der Heide, G. Dijkstra, R.J. Porte, J.H. Kleibeuker, and E.B. Haagsma Smoking behavior in liver transplant recipients Liver Transpl 15 2009 648 655
145. L. Roels, and A. Rahmel The European experience Transpl Int 24 2011 350 367
146. K. Hawton, H. Bergen, S. Simkin, S. Dodd, P. Pocock, W. Bernal, and et al. Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses BMJ 346 2013 f403
147. R. Matesanz Organ procurement in Spain Lancet 340 1992 733
148. R. Matesanz, R. Marazuela, B. Dominguez-Gil, E. Coll, B. Mahillo, and G. de la Rosa The 40 donors per million population plan: an action plan for improvement of organ donation and transplantation in Spain Transplant Proc 41 2009 3453 3456
149. Consensus document of the Spanish Society of Liver Transplantation Gastroenterol Hepatol 31 2008 82 91
150. Consensus document of the Spanish Society of Liver Transplantation. Waiting lists, liver transplantation and quality indicators Gastroenterol Hepatol 32 2009 702 716
151. III Consensus Meeting of the Spanish Society of Liver Transplantation. Hepatitis C, living-donor liver transplantation, quality of liver grafts and of liver transplantation programs Cir Esp 89 2011 487 504
152. B. Fosby, T.H. Karlsen, and E. Melum Recurrence and rejection in liver transplantation for primary sclerosing cholangitis World J Gastroenterol 18 2012 1 15
153. J. De Meester, G.G. Persijn, T. Wujciak, G. Opelz, and Y. Vanrenterghem The new Eurotransplant Kidney Allocation System: report one year after implementation. Eurotransplant International Foundation Transplantation 66 1998 1154 1159
154. J. Neuberger, and P.A. Ubel Finding a place for public preferences in liver allocation decisions Transplantation 70 2000 1411 1413
155. P. Muiesan, R. Girlanda, W. Jassem, H.V. Melendez, J. O'Grady, M. Bowles, and et al. Single-center experience with liver transplantation from controlled non-heartbeating donors: a viable source of grafts Ann Surg 242 2005 732 738
156. Eurotransplant Manual. 5th Ed. 2010. 18.
157. G. Kootstra, J.H. Daemen, and A.P. Oomen Categories of non-heart-beating donors Transplant Proc 27 1995 2893 2894
158. P.E. Morrissey, and A.P. Monaco Donation after circulatory death: current practices, ongoing challenges, and potential improvements Transplantation 97 2014 258 264
159. R. Hernandez-Alejandro, Y. Caumartin, C. Chent, M.A. Levstik, D. Quan, N. Muirhead, and et al. Kidney and liver transplants from donors after cardiac death: initial experience at the London Health Sciences Centre Can J Surg 53 2010 93 102
160. D.L. Schmucker, and H. Sanchez Liver regeneration and aging: a current perspective Curr Gerontol Geriatr Res 2011 2011 526379
161. R.J. Ploeg, A.M. D'Alessandro, S.J. Knechtle, M.D. Stegall, J.D. Pirsch, R.M. Hoffmann, and et al. Risk factors for primary dysfunction after liver transplantation-a multivariate analysis Transplantation 55 1993 807 813
162. Y. Park, R. Hirose, J.L. Coatney, L. Ferrell, M. Behrends, J.P. Roberts, and et al. Ischemia-reperfusion injury is more severe in older versus young rat livers J Surg Res 137 2007 96 102
163. M.F. Chedid, C.B. Rosen, S.L. Nyberg, and J.K. Heimbach Excellent long-term patient and graft survival are possible with appropriate use of livers from deceased septuagenarian and octogenarian donors HPB (Oxford) 16 2014 852 858
164. T. Uemura, L.E. Nikkel, C.S. Hollenbeak, V. Ramprasad, E. Schaefer, and Z. Kadry How can we utilize livers from advanced aged donors for liver transplantation for hepatitis C? Transpl Int 25 2012 671 679
165. J. Zheng, J. Xiang, J. Zhou, Z. Li, Z. Hu, C.M. Lo, and et al. Liver grafts for transplantation from donors with diabetes: an analysis of the Scientific Registry of Transplant Recipients database PLoS One 9 2014 e98104
166. K. Karayalcin, D.F. Mirza, R.F. Harrison, R.F. Da Silva, S.G. Hubscher, A.D. Mayer, and et al. The role of dynamic and morphological studies in the assessment of potential liver donors Transplantation 57 1994 1323 1327
167. A.M. D'Alessandro, M. Kalayoglu, H.W. Sollinger, R.M. Hoffmann, A. Reed, S.J. Knechtle, and et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation Transplantation 51 1991 157 163
168. J.P. Deroose, G. Kazemier, P. Zondervan, J.N. Ijzermans, H.J. Metselaar, and I.P. Alwayn Hepatic steatosis is not always a contraindication for cadaveric liver transplantation HPB (Oxford) 13 2011 417 425
169. D. Verran, T. Kusyk, D. Painter, J. Fisher, D. Koorey, S. Strasser, and et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation Liver Transpl 9 2003 500 505
170. P. Dutkowski, A. Schlegel, K. Slankamenac, C.E. Oberkofler, R. Adam, A.K. Burroughs, and et al. The use of fatty liver grafts in modern allocation systems: risk assessment by the balance of risk (BAR) score Ann Surg 256 2012 861 868 Discussion 8-9
171. M. Angelico, A. Nardi, T. Marianelli, L. Caccamo, R. Romagnoli, G. Tisone, and et al. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study J Hepatol 58 2013 715 723
172. P.P. Joya-Vazquez, F.S. Dodson, I. Dvorchik, E. Gray, A. Chesky, A.J. Demetris, and et al. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis Transplantation 73 2002 1598 1602
173. E. Cholongitas, G.V. Papatheodoridis, and A.K. Burroughs Liver grafts from anti-hepatitis B core positive donors: a systematic review J Hepatol 52 2010 272 279
174. S. Yu, J. Yu, W. Zhang, L. Cheng, Y. Ye, L. Geng, and et al. Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation J Hepatol 61 2014 809 815
175. Y. Choi, J.Y. Choi, N.J. Yi, K. Lee, S. Mori, G. Hong, and et al. Liver transplantation for HBsAg-positive recipients using grafts from HBsAg-positive deceased donors Transpl Int 26 2013 1173 1183
176. E. Alvaro, M. Abradelo, A. Fuertes, A. Manrique, F. Colina, C. Alegre, and et al. Liver transplantation from anti-hepatitis C virus-positive donors: our experience Transplant Proc 44 2012 1475 1478
177. S. Saab, A.J. Chang, S. Comulada, S.K. Geevarghese, R.D. Anselmo, F. Durazo, and et al. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation Liver Transpl 9 2003 1053 1061
178. P.G. Northup, C.K. Argo, D.T. Nguyen, M.A. McBride, S.C. Kumer, T.M. Schmitt, and et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis Transpl Int 23 2010 1038 1044
179. A. Coilly, V. Furlan, B. Roche, C. Barau, C. Noel, L. Bonhomme-Faivre, and et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence Antimicrob Agents Chemother 56 2012 5728 5734
180. A. Coilly, B. Roche, J. Dumortier, V. Leroy, D. Botta-Fridlund, S. Radenne, and et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience J Hepatol 60 2014 78 86
181. J.M. Miro, M. Montejo, L. Castells, A. Rafecas, S. Moreno, F. Aguero, and et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study Am J Transplant 12 2012 1866 1876
182. Potential transmission of viral hepatitis through use of stored blood vessels as conduits in organ transplantation-Pennsylvania, 2009 MMWR Morb Mortal Wkly Rep 60 2011 172 174
183. C.J. Watson, R. Roberts, K.A. Wright, D.C. Greenberg, B.A. Rous, C.H. Brown, and et al. How safe is it to transplant organs from deceased donors with primary intracranial malignancy? An analysis of UK Registry data Am J Transplant 10 2010 1437 1444
184. S. Feng, J.F. Buell, R.S. Chari, J.M. DiMaio, and D.W. Hanto Tumors and transplantation: the 2003 Third Annual ASTS State-of-the-Art Winter Symposium Am J Transplant 3 2003 1481 1487
185. S. Kusne, and J. Smilack Transmission of West Nile virus by organ transplantation Liver Transpl 11 2005 239 241
186. R.J. Nett, M.J. Kuehnert, M.G. Ison, J.P. Orlowski, M. Fischer, and J.E. Staples Current practices and evaluation of screening solid organ donors for West Nile virus Transpl Infect Dis 14 2012 268 277
187. M.I. Morris, J.S. Daly, E. Blumberg, D. Kumar, M. Sester, N. Schluger, and et al. Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report Am J Transplant 12 2012 2288 2300
188. J.E. Holty, M.K. Gould, L. Meinke, E.B. Keeffe, and S.J. Ruoss Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data Liver Transpl 15 2009 894 906
189. M.G. Ison, and P. Grossi Donor-derived infections in solid organ transplantation Am J Transplant 13 2013 22 30
190. C.D. Sifri, and M.G. Ison Highly resistant bacteria and donor-derived infections: treading in uncharted territory Transpl Infect Dis 14 2012 223 228
191. E. Cerutti, C. Stratta, R. Romagnoli, R. Serra, M. Lepore, F. Fop, and et al. Bacterial- and fungal-positive cultures in organ donors: clinical impact in liver transplantation Liver Transpl 12 2006 1253 1259
192. C. Gonzalez-Segura, M. Pascual, L. Garcia Huete, R. Canizares, J. Torras, L. Corral, and et al. Donors with positive blood culture: could they transmit infections to the recipients? Transplant Proc 37 2005 3664 3666
193. S.A. Fischer, and K. Lu Screening of donor and recipient in solid organ transplantation Am J Transplant 13 2013 9 21
194. J.D. Altclas, L. Barcan, C. Nagel, R. Lattes, and A. Riarte Organ transplantation and Chagas disease JAMA 299 2008 1134 Author reply-5
195. P.V. Chin-Hong, B.S. Schwartz, C. Bern, S.P. Montgomery, S. Kontak, B. Kubak, and et al. Screening and treatment of chagas disease in organ transplant recipients in the United States: recommendations from the chagas in transplant working group Am J Transplant 11 2011 672 680
196. W.M. Bennett, J.F. Nespral, M.W. Rosson, and K.M. McEvoy Use of organs for transplantation from a donor with primary meningoencephalitis due to Naegleria fowleri Am J Transplant 8 2008 1334 1335
197. N. Singh, S. Huprikar, S.D. Burdette, M.I. Morris, J.E. Blair, and L.J. Wheat Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, infectious diseases community of practice Am J Transplant 12 2012 2414 2428
198. S. Feng, N.P. Goodrich, J.L. Bragg-Gresham, D.M. Dykstra, J.D. Punch, M.A. DebRoy, and et al. Characteristics associated with liver graft failure: the concept of a donor risk index Am J Transplant 6 2006 783 790
199. P. Dutkowski, C.E. Oberkofler, K. Slankamenac, M.A. Puhan, E. Schadde, B. Mullhaupt, and et al. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era Ann Surg 254 2011 745 753 Discussion 53
200. K. Tanaka, Y. Ogura, T. Kiuchi, Y. Inomata, S. Uemoto, and H. Furukawa Living donor liver transplantation: Eastern experiences HPB (Oxford) 6 2004 88 94
201. F.X. Gonzalez, J.C. Garcia-Valdecasas, L. Grande, J.L. Pacheco, E. Cugat, J. Fuster, and et al. Vena cava vascular reconstruction during orthotopic liver transplantation: a comparative study Liver Transpl Surg 4 1998 133 140
202. P. Parrilla, F. Sanchez-Bueno, J. Figueras, E. Jaurrieta, J. Mir, C. Margarit, and et al. Analysis of the complications of the piggy-back technique in 1,112 liver transplants Transplantation 67 1999 1214 1217
203. J. Figueras, L. Llado, E. Ramos, E. Jaurrieta, A. Rafecas, J. Fabregat, and et al. Temporary portocaval shunt during liver transplantation with vena cava preservation. Results of a prospective randomized study Liver Transpl 7 2001 904 911
204. S. Yamamoto, H.E. Wilczek, G. Nowak, M. Larsson, A. Oksanen, T. Iwata, and et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years Am J Transplant 7 2007 2597 2604
205. L.F. Pacheco-Moreira, M.E. de Oliveira, E. Balbi, A.C. da Silva, R. Miecznikowski, L.J. de Faria, and et al. A new technical option for domino liver transplantation Liver Transpl 9 2003 632 633
206. J.I. Moon, C.H. Kwon, J.W. Joh, G.O. Jung, G.S. Choi, J.B. Park, and et al. Safety of small-for-size grafts in adult-to-adult living donor liver transplantation using the right lobe Liver Transpl 16 2010 864 869
207. J.P. Lodge, D. Dasgupta, K.R. Prasad, M. Attia, G.J. Toogood, M. Davies, and et al. Emergency subtotal hepatectomy: a new concept for acetaminophen-induced acute liver failure: temporary hepatic support by auxiliary orthotopic liver transplantation enables long-term success Ann Surg 247 2008 238 249
208. M. Rela, P. Muiesan, H. Vilca-Melendez, A. Dhawan, A. Baker, G. Mieli-Vergani, and et al. Auxiliary partial orthotopic liver transplantation for Crigler-Najjar syndrome type I Ann Surg 229 1999 565 569
209. B. Brandsaeter, K. Hockerstedt, S. Friman, B.G. Ericzon, P. Kirkegaard, H. Isoniemi, and et al. Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation-12 years experience in the nordic countries Liver Transpl 8 2002 1055 1062
210. I.W. Liou, and A.M. Larson Role of liver transplantation in acute liver failure Semin Liver Dis 28 2008 201 209
211. B. van Hoek, J. de Boer, K. Boudjema, R. Williams, O. Corsmit, and O.T. Terpstra Auxiliary versus orthotopic liver transplantation for acute liver failure. EURALT Study Group. European Auxiliary Liver Transplant Registry J Hepatol 30 1999 699 705
212. D.C. Broering, J. Schulte am Esch, L. Fischer, and X. Rogiers Split liver transplantation HPB (Oxford) 6 2004 76 82
213. R. Pichlmayr, B. Ringe, G. Gubernatis, J. Hauss, and H. Bunzendahl Transplantation of a donor liver to 2 recipients (splitting transplantation)-a new method in the further development of segmental liver transplantation Langenbecks Arch Chir 373 1988 127 130
214. X. Rogiers, M. Malago, K.A. Gawad, R. Kuhlencordt, G. Froschle, E. Sturm, and et al. One year of experience with extended application and modified techniques of split liver transplantation Transplantation 61 1996 1059 1061
215. W.C. Lee, K.M. Chan, H.S. Chou, T.J. Wu, C.F. Lee, R.S. Soong, and et al. Feasibility of split liver transplantation for 2 adults in the model of end-stage liver disease era Ann Surg 258 2013 306 311
216. P.A. Vagefi, J. Parekh, N.L. Ascher, J.P. Roberts, and C.E. Freise Outcomes with split liver transplantation in 106 recipients: the University of California, San Francisco, experience from 1993 to 2010 Arch Surg 146 2011 1052 1059
217. P.A. Singer, M. Siegler, P.F. Whitington, J.D. Lantos, J.C. Emond, J.R. Thistlethwaite, and et al. Ethics of liver transplantation with living donors N Engl J Med 321 1989 620 622
218. Y. Yamaoka, M. Washida, K. Honda, K. Tanaka, K. Mori, Y. Shimahara, and et al. Liver transplantation using a right lobe graft from a living related donor Transplantation 57 1994 1127 1130
219. C. Wilms, J. Walter, M. Kaptein, L. Mueller, C. Lenk, M. Sterneck, and et al. Long-term outcome of split liver transplantation using right extended grafts in adulthood: a matched pair analysis Ann Surg 244 2006 865 872 Discussion 72-73
220. S. Hwang, S.G. Lee, Y.J. Lee, K.B. Sung, K.M. Park, K.H. Kim, and et al. Lessons learned from 1,000 living donor liver transplantations in a single center: how to make living donations safe Liver Transpl 12 2006 920 927
221. D. Dindo, N. Demartines, and P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg 240 2004 205 213
222. M.M. Abecassis, R.A. Fisher, K.M. Olthoff, C.E. Freise, D.R. Rodrigo, B. Samstein, and et al. Complications of living donor hepatic lobectomy-a comprehensive report Am J Transplant 12 2012 1208 1217
223. J. Iwasaki, T. Iida, M. Mizumoto, T. Uemura, S. Yagi, T. Hori, and et al. Donor morbidity in right and left hemiliver living donor liver transplantation: the impact of graft selection and surgical innovation on donor safety Transpl Int 27 2014 1205 1213
224. Y.L. Cheah, M.A. Simpson, J.J. Pomposelli, and E.A. Pomfret Incidence of death and potentially life-threatening near-miss events in living donor hepatic lobectomy: a world-wide survey Liver Transpl 19 2013 499 506
225. D.N. Samonakis, G. Germani, and A.K. Burroughs Immunosuppression and HCV recurrence after liver transplantation J Hepatol 56 2012 973 983
226. A.A. Pillai, and J. Levitsky Overview of immunosuppression in liver transplantation World J Gastroenterol 15 2009 4225 4233
227. M.W. Fried, M. Buti, G.J. Dore, R. Flisiak, P. Ferenci, I. Jacobson, and et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study Hepatology 58 2013 1918 1929
228. M.M. Mourad, C. Liossis, B.K. Gunson, H. Mergental, J. Isaac, P. Muiesan, and et al. Etiology and management of hepatic artery thrombosis after adult liver transplantation Liver Transpl 20 2014 713 723
229. R. Rull, J.C. Garcia Valdecasas, L. Grande, J. Fuster, A.M. Lacy, F.X. Gonzalez, and et al. Intrahepatic biliary lesions after orthotopic liver transplantation Transpl Int 14 2001 129 134
230. J.M. Lee, G.Y. Ko, K.B. Sung, D.I. Gwon, H.K. Yoon, and S.G. Lee Long-term efficacy of stent placement for treating inferior vena cava stenosis following liver transplantation Liver Transpl 16 2010 513 519
231. M. Guimaraes, R. Uflacker, C. Schonholz, C. Hannegan, and J.B. Selby Stent migration complicating treatment of inferior vena cava stenosis after orthotopic liver transplantation J Vasc Interv Radiol 16 2005 1247 1252
232. M. Audet, T. Piardi, F. Panaro, M. Cag, H. Habibeh, F. Gheza, and et al. Four hundred and twenty-three consecutive adults piggy-back liver transplantations with the three suprahepatic veins: was the portal systemic shunt required? J Gastroenterol Hepatol 25 2010 591 596
233. P. Bhangui, C. Lim, C. Salloum, P. Andreani, M. Sebbagh, E. Hoti, and et al. Caval inflow to the graft for liver transplantation in patients with diffuse portal vein thrombosis: a 12-year experience Ann Surg 254 2011 1008 1016
234. M.C. Londono, D. Balderramo, and A. Cardenas Management of biliary complications after orthotopic liver transplantation: the role of endoscopy World J Gastroenterol 14 2008 493 497
235. S. Sanchez Cabus, D. Calatayud, R. Garcia-Roca, J. Ferrer, J. Marti, M. Navasa, and et al. The biliary complications in live donor liver transplant do not affect the long-term results Cir Esp 91 2013 17 24
236. F.W. Selck, E.B. Grossman, L.E. Ratner, and J.F. Renz Utilization, outcomes, and retransplantation of liver allografts from donation after cardiac death: implications for further expansion of the deceased-donor pool Ann Surg 248 2008 599 607
237. I.W. Graziadei, R.H. Wiesner, K.P. Batts, P.J. Marotta, N.F. LaRusso, M.K. Porayko, and et al. Recurrence of primary sclerosing cholangitis following liver transplantation Hepatology 29 1999 1050 1056
238. S. Nishida, N. Nakamura, J. Kadono, T. Komokata, R. Sakata, J.R. Madariaga, and et al. Intrahepatic biliary strictures after liver transplantation J Hepatobiliary Pancreat Surg 13 2006 511 516
239. S. Sharma, A. Gurakar, and N. Jabbour Biliary strictures following liver transplantation: past, present and preventive strategies Liver Transpl 14 2008 759 769
240. R.C. Verdonk, C.I. Buis, R.J. Porte, E.J. van der Jagt, A.J. Limburg, A.P. van den Berg, and et al. Anastomotic biliary strictures after liver transplantation: causes and consequences Liver Transpl 12 2006 726 735
241. M.M. Linhares, A.M. Gonzalez, S.M. Goldman, R.D. Coelho, N.Y. Sato, R.M. Moura, and et al. Magnetic resonance cholangiography in the diagnosis of biliary complications after orthotopic liver transplantation Transplant Proc 36 2004 947 948
242. R.S. Sung, D.A. Campbell Jr., S.M. Rudich, J.D. Punch, V.L. Shieck, J.M. Armstrong, and et al. Long-term follow-up of percutaneous transhepatic balloon cholangioplasty in the management of biliary strictures after liver transplantation Transplantation 77 2004 110 115
243. S.A. Shah, D.R. Grant, I.D. McGilvray, P.D. Greig, M. Selzner, L.B. Lilly, and et al. Biliary strictures in 130 consecutive right lobe living donor liver transplant recipients: results of a Western center Am J Transplant 7 2007 161 167
244. S. Hwang, S.G. Lee, K.B. Sung, K.M. Park, K.H. Kim, C.S. Ahn, and et al. Long-term incidence, risk factors, and management of biliary complications after adult living donor liver transplantation Liver Transpl 12 2006 831 838
245. H. Tashiro, T. Itamoto, T. Sasaki, H. Ohdan, Y. Fudaba, H. Amano, and et al. Biliary complications after duct-to-duct biliary reconstruction in living-donor liver transplantation: causes and treatment World J Surg 31 2007 2222 2229
246. P.S. Yoo, V. Umman, M.I. Rodriguez-Davalos, and S.H. Emre Retransplantation of the liver: review of current literature for decision making and technical considerations Transplant Proc 45 2013 854 859
247. R. Pfitzmann, B. Benscheidt, J.M. Langrehr, G. Schumacher, R. Neuhaus, and P. Neuhaus Trends and experiences in liver retransplantation over 15 years Liver Transpl 13 2007 248 257
248. G.H. Chen, B.S. Fu, C.J. Cai, M.Q. Lu, Y. Yang, S.H. Yi, and et al. A single-center experience of retransplantation for liver transplant recipients with a failing graft Transplant Proc 40 2008 1485 1487
249. K.D. Watt, E.R. Lyden, and T.M. McCashland Poor survival after liver retransplantation: is hepatitis C to blame? Liver Transpl 9 2003 1019 1024
250. M. Ghabril, R. Dickson, and R. Wiesner Improving outcomes of liver retransplantation: an analysis of trends and the impact of Hepatitis C infection Am J Transplant 8 2008 404 411
251. H.R. Rosen, J.P. Madden, and P. Martin A model to predict survival following liver retransplantation Hepatology 29 1999 365 370
252. F.Y. Yao, S. Saab, N.M. Bass, R. Hirose, D. Ly, N. Terrault, and et al. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores Hepatology 39 2004 230 238
253. R.H. Wiesner, and J.J. Fung Present state of immunosuppressive therapy in liver transplant recipients Liver Transpl 17 2011 S1 S9
254. V.C. McAlister, E. Haddad, E. Renouf, R.A. Malthaner, M.S. Kjaer, and L.L. Gluud Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis Am J Transplant 6 2006 1578 1585
255. J.G. O'Grady, P. Hardy, A.K. Burroughs, and D. Elbourne Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years Am J Transplant 7 2007 137 141
256. J. Dumortier, O. Guillaud, and O. Boillot Conversion from twice daily tacrolimus to once daily tacrolimus in long-term stable liver transplant recipients: a single-center experience with 394 patients Liver Transpl 19 2013 529 533
257. P. Trunecka, O. Boillot, D. Seehofer, A.D. Pinna, L. Fischer, B.G. Ericzon, and et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation Am J Transplant 10 2010 2313 2323
258. S. Beckebaum, S. Iacob, D. Sweid, G.C. Sotiropoulos, F. Saner, G. Kaiser, and et al. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation Transpl Int 24 2011 666 675
259. O.H. Nielsen, B. Vainer, and J. Rask-Madsen Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine Aliment Pharmacol Ther 15 2001 1699 1708
260. R. Wiesner, J. Rabkin, G. Klintmalm, S. McDiarmid, A. Langnas, J. Punch, and et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients Liver Transpl 7 2001 442 450
261. M. Sterneck, L. Fischer, C. Gahlemann, M. Gundlach, X. Rogiers, and C. Broelsch Mycophenolate mofetil for prevention of liver allograft rejection: initial results of a controlled clinical trial Ann Transplant 5 2000 43 46
262. L. Fischer, M. Sterneck, C.G. Gahlemann, M. Malago, X. Rogiers, and C.E. Broelsch A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients Transplant Proc 32 2000 2125 2127
263. K. Budde, J. Curtis, G. Knoll, L. Chan, H.H. Neumayer, Y. Seifu, and et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study Am J Transplant 4 2004 237 243
264. G. Ciancio, G.W. Burke, J.J. Gaynor, D. Roth, J. Sageshima, W. Kupin, and et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up Transplantation 86 2008 67 74
265. M. Salvadori, H. Holzer, A. de Mattos, H. Sollinger, W. Arns, F. Oppenheimer, and et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients Am J Transplant 4 2004 231 236
266. A. Johnston, X. He, and D.W. Holt Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients Transplantation 82 2006 1413 1418
267. G.P. Cantisani, M.L. Zanotelli, A.L. Gleisner, A. de Mello Brandao, and C.A. Marroni Enteric-coated mycophenolate sodium experience in liver transplant patients Transplant Proc 38 2006 932 933
268. M. Miras, F. Carballo, J. Egea, C. Martinez, M.R. Alvarez-Lopez, F. Sanchez-Bueno, and et al. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications Transplant Proc 39 2007 2314 2317
269. J.C. Dunkelberg, J.F. Trotter, M. Wachs, T. Bak, M. Kugelmas, T. Steinberg, and et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications Liver Transpl 9 2003 463 468
270. V.C. McAlister, K.M. Peltekian, D.A. Malatjalian, S. Colohan, S. MacDonald, H. Bitter-Suermann, and et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus Liver Transpl 7 2001 701 708
271. G.J. McKenna, and J.F. Trotter Sirolimus-it doesn't deserve its bad Rap(a) J Hepatol 56 2012 285 287
272. M.G. Murgia, S. Jordan, and B.D. Kahan The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients Kidney Int 49 1996 209 216
273. P. Neuhaus, P.A. Clavien, D. Kittur, M. Salizzoni, A. Rimola, K. Abeywickrama, and et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial Liver Transpl 8 2002 132 142
274. A.D. Goralczyk, N. Hauke, N. Bari, T.Y. Tsui, T. Lorf, and A. Obed Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies Hepatology 54 2011 541 554
275. Y. Calmus, J.R. Scheele, I. Gonzalez-Pinto, E.J. Jaurrieta, E. Klar, G.P. Pageaux, and et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients Liver Transpl 8 2002 123 131
276. R. Hirose, J.P. Roberts, D. Quan, R.W. Osorio, C. Freise, N.L. Ascher, and et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation Transplantation 69 2000 307 311
277. I. Bajjoka, L. Hsaiky, K. Brown, and M. Abouljoud Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors Liver Transpl 14 2008 66 72
278. T. Soliman, H. Hetz, C. Burghuber, G. Gyori, G. Silberhumer, R. Steininger, and et al. Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation Transpl Int 20 2007 447 452
279. G.B. Klintmalm Immunosuppression, generic drugs and the FDA Am J Transplant 11 2011 1765 1766
280. J. Trofe-Clark, S. Gabardi, L. McDevitt-Potter, and R.R. Alloway Immunosuppression, generic drugs and the FDA Am J Transplant 12 2012 792 793 Author reply 4
281. Latran, and M. Latran Response to Klintmalm on the use of generic immunosuppression Am J Transplant 12 2012 791 Author reply 4
282. R.R. Alloway, R. Isaacs, K. Lake, P. Hoyer, R. First, H. Helderman, and et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants Am J Transplant 3 2003 1211 1215
283. D. Taube, G. Jones, J. O'Beirne, L. Wennberg, A. Connor, A. Rasmussen, and et al. Generic tacrolimus in solid organ transplantation Clin Transplant 28 2014 623 632
284. C.R. Ensor, J. Trofe-Clark, S. Gabardi, L.M. McDevitt-Potter, and M.A. Shullo Generic maintenance immunosuppression in solid organ transplant recipients Pharmacotherapy 31 2011 1111 1129
285. A.O. Ojo, P.J. Held, F.K. Port, R.A. Wolfe, A.B. Leichtman, E.W. Young, and et al. Chronic renal failure after transplantation of a nonrenal organ N Engl J Med 349 2003 931 940
286. A.M. de Mattos, A.J. Olyaei, and W.M. Bennett Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future Am J Kidney Dis 35 2000 333 346
287. Y. Calmus, N. Kamar, J. Gugenheim, C. Duvoux, C. Ducerf, P. Wolf, and et al. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients Transplantation 89 2010 1504 1510
288. J.M. Neuberger, R.D. Mamelok, P. Neuhaus, J. Pirenne, D. Samuel, H. Isoniemi, and et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study Am J Transplant 9 2009 327 336
289. E.M. Yoshida, P.J. Marotta, P.D. Greig, N.M. Kneteman, D. Marleau, M. Cantarovich, and et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial Liver Transpl 11 2005 1064 1072
290. M. Biselli, G. Vitale, A. Gramenzi, A. Riili, S. Berardi, C. Camma, and et al. Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant Clin Transplant 23 2009 191 198
291. V.R. Cicinnati, Z. Yu, C.G. Klein, G.C. Sotiropoulos, F. Saner, M. Malago, and et al. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients-assessment of renal and allograft function, cardiovascular risk factors and immune monitoring Aliment Pharmacol Ther 26 2007 1195 1208
292. C. Creput, F. Blandin, B. Deroure, B. Roche, F. Saliba, B. Charpentier, and et al. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation Liver Transpl 13 2007 1004 1010
293. R.O. Koch, I.W. Graziadei, F. Schulz, K. Nachbaur, A. Konigsrainer, R. Margreiter, and et al. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction Transpl Int 17 2004 518 524
294. G.P. Pageaux, L. Rostaing, Y. Calmus, C. Duvoux, C. Vanlemmens, J. Hardgwissen, and et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation Liver Transpl 12 2006 1755 1760
295. D.J. Reich, P.A. Clavien, and E.E. Hodge Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results Transplantation 80 2005 18 25
296. S. Dharancy, A. Iannelli, A. Hulin, N. Declerck, A.S. Schneck, P. Mathurin, and et al. Mycophenolate mofetil monotherapy for severe side effects of calcineurin inhibitors following liver transplantation Am J Transplant 9 2009 610 613
297. J.M. Moreno Planas, V. Cuervas-Mons Martinez, E. Rubio Gonzalez, A. Gomez Cruz, J. Lopez-Monclus, V. Sanchez-Turrion, and et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation Am J Transplant 4 2004 1650 1655
298. M.L. Raimondo, L. Dagher, G.V. Papatheodoridis, N. Rolando, D.W. Patch, B.R. Davidson, and et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation Transplantation 75 2003 186 190
299. R. Robson, J.M. Cecka, G. Opelz, M. Budde, and S. Sacks Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil Am J Transplant 5 2005 2954 2960
300. H.J. Schlitt, A. Barkmann, K.H. Boker, H.H. Schmidt, N. Emmanouilidis, J. Rosenau, and et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study Lancet 357 2001 587 591
301. C. Duvoux, and G.P. Pageaux Immunosuppression in liver transplant recipients with renal impairment J Hepatol 54 2011 1041 1054
302. B.S. Chang, W.S. Hong, E. Lee, S.M. Yeo, I.S. Bang, Y.H. Chung, and et al. Ultramicroscopic observations on morphological changes in hair during 25 years of weathering Forensic Sci Int 151 2005 193 200
303. M. Hong, P.W. Angus, R.M. Jones, R.B. Vaughan, and P.J. Gow Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction Clin Transplant 19 2005 193 198
304. W.J. Sandborn, J.E. Hay, M.K. Porayko, G.J. Gores, J.L. Steers, R.A. Krom, and et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection Hepatology 19 1994 925 932
305. G. Germani, M. Pleguezuelo, F. Villamil, S. Vaghjiani, E. Tsochatzis, L. Andreana, and et al. Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil Am J Transplant 9 2009 1725 1731
306. S.K. Asrani, M.D. Leise, C.P. West, M.H. Murad, R.A. Pedersen, P.J. Erwin, and et al. Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis Hepatology 52 2010 1360 1370
307. M.F. Abdelmalek, A. Humar, F. Stickel, P. Andreone, A. Pascher, E. Barroso, and et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial Am J Transplant 12 2012 694 705
308. L. Teperman, D. Moonka, A. Sebastian, L. Sher, P. Marotta, C. Marsh, and et al. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial Liver Transpl 19 2013 675 689
309. J.F. Castroagudin, E. Molina, R. Romero, E. Otero, S. Tome, and E. Varo Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction Liver Transpl 15 2009 1792 1797
310. P. De Simone, H.J. Metselaar, L. Fischer, J. Dumortier, K. Boudjema, J. Hardwigsen, and et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial Liver Transpl 15 2009 1262 1269
311. L. Fischer, J. Klempnauer, S. Beckebaum, H.J. Metselaar, P. Neuhaus, P. Schemmer, and et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT Am J Transplant 12 2012 1855 1865
312. M. Sterneck, G.M. Kaiser, N. Heyne, N. Richter, F. Rauchfuss, A. Pascher, and et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation Am J Transplant 14 2014 701 710
313. P. De Simone, F. Nevens, L. De Carlis, H.J. Metselaar, S. Beckebaum, F. Saliba, and et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial Am J Transplant 12 2012 3008 3020
314. F. Saliba, P. De Simone, F. Nevens, L. De Carlis, H.J. Metselaar, S. Beckebaum, and et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study Am J Transplant 13 2013 1734 1745
315. K. Watashi, M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes Hepatology 38 2003 1282 1288
316. M. Berenguer, A. Royuela, and J. Zamora Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis Liver Transpl 13 2007 21 29
317. R.J. Firpi, C. Soldevila-Pico, G.G. Morelli, R. Cabrera, C. Levy, V.C. Clark, and et al. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study Dig Dis Sci 55 2010 196 203
318. M. Berenguer, F.X. Lopez-Labrador, H.B. Greenberg, and T.L. Wright Hepatitis C virus and the host: an imbalance induced by immunosuppression? Hepatology 32 2000 433 435
319. U.P. Neumann, T. Berg, M. Bahra, D. Seehofer, J.M. Langrehr, R. Neuhaus, and et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C J Hepatol 41 2004 830 836
320. M. Berenguer, V. Aguilera, M. Prieto, F. San Juan, J.M. Rayon, S. Benlloch, and et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression J Hepatol 44 2006 717 722
321. D.N. Samonakis, C.K. Triantos, U. Thalheimer, A. Quaglia, G. Leandro, R. Teixeira, and et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation Liver Transpl 11 2005 386 395
322. M. Vivarelli, P. Burra, G. La Barba, D. Canova, M. Senzolo, A. Cucchetti, and et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study J Hepatol 47 2007 793 798
323. P. Manousou, E. Cholongitas, D. Samonakis, E. Tsochatzis, A. Corbani, A.P. Dhillon, and et al. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes Gut 63 2014 1005 1013
324. F. Filipponi, F. Callea, M. Salizzoni, G.L. Grazi, L.R. Fassati, M. Rossi, and et al. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine Transplantation 78 2004 1488 1495
325. T. Kato, J.J. Gaynor, H. Yoshida, M. Montalvano, H. Takahashi, N. Pyrsopoulos, and et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year Transplantation 84 2007 829 835
326. G.B. Klintmalm, G.L. Davis, L. Teperman, G.J. Netto, K. Washburn, S.M. Rudich, and et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C Liver Transpl 17 2011 1394 1403
327. D.L. Segev, S.M. Sozio, E.J. Shin, S.M. Nazarian, H. Nathan, P.J. Thuluvath, and et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials Liver Transpl 14 2008 512 525
328. A. Kornberg, B. Kupper, A. Tannapfel, M. Hommann, and J. Scheele Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation Int Immunopharmacol 5 2005 107 115
329. E. Patsenker, V. Schneider, M. Ledermann, H. Saegesser, C. Dorn, C. Hellerbrand, and et al. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis J Hepatol 55 2011 388 398
330. P. Mannova, and L. Beretta Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication J Virol 79 2005 8742 8749
331. G.J. McKenna, J.F. Trotter, E. Klintmalm, N. Onaca, R. Ruiz, L.W. Jennings, and et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression Am J Transplant 11 2011 2379 2387
332. P. De Simone, P. Carrai, A. Precisi, S. Petruccelli, L. Baldoni, E. Balzano, and et al. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function Transpl Int 22 2009 279 286
333. N. De Ruvo, A. Cucchetti, A. Lauro, M. Masetti, N. Cautero, F. Di Benedetto, and et al. Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation Transplantation 80 2005 8 12
334. M. Garcia-Saenz-de-Sicilia, M.A. Olivera-Martinez, W.J. Grant, D.F. Mercer, C. Baojjang, A. Langnas, and et al. Impact of anti-thymocyte globulin during immunosuppression induction in patients with hepatitis C after liver transplantation Dig Dis Sci 59 2014 2804 2812
335. A. Marcos, B. Eghtesad, J.J. Fung, P. Fontes, K. Patel, M. Devera, and et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus Transplantation 78 2004 966 971
336. M. Hojo, T. Morimoto, M. Maluccio, T. Asano, K. Morimoto, M. Lagman, and et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism Nature 397 1999 530 534
337. C.E. Freise, L. Ferrell, T. Liu, N.L. Ascher, and J.P. Roberts Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma Transplantation 67 1999 510 513
338. M. Rodriguez-Peralvarez, E. Tsochatzis, M.C. Naveas, G. Pieri, C. Garcia-Caparros, J. O'Beirne, and et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma J Hepatol 59 2013 1193 1199
339. M. Vivarelli, R. Bellusci, A. Cucchetti, G. Cavrini, N. De Ruvo, A.A. Aden, and et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 74 2002 1746 1751
340. T. Decaens, F. Roudot-Thoraval, S. Bresson-Hadni, C. Meyer, J. Gugenheim, F. Durand, and et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients World J Gastroenterol 12 2006 7319 7325
341. M. Vivarelli, A. Cucchetti, G. La Barba, M. Ravaioli, M. Del Gaudio, A. Lauro, and et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence Ann Surg 248 2008 857 862
342. W. Liang, D. Wang, X. Ling, A.A. Kao, Y. Kong, Y. Shang, and et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis Liver Transpl 18 2012 62 69
343. K.V. Menon, A.R. Hakeem, and N.D. Heaton Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma Aliment Pharmacol Ther 37 2013 411 419
344. A.A. Schnitzbauer, C. Zuelke, C. Graeb, J. Rochon, I. Bilbao, P. Burra, and et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma BMC Cancer 10 2010 190
345. E.K. Geissler, A.A. Schnitzbauer, C. Zülke, P.E. Lamby, A. Proneth, C. Duvoux, and et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma Transplantation 100 2016 116 125
346. H.S. Shiah, C.Y. Chen, C.Y. Dai, C.F. Hsiao, Y.J. Lin, W.C. Su, and et al. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma Aliment Pharmacol Ther 37 2013 62 73
347. A.X. Zhu, T.A. Abrams, R. Miksad, L.S. Blaszkowsky, J.A. Meyerhardt, H. Zheng, and et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma Cancer 117 2011 5094 5102
348. A.S. Tjon, J. Sint Nicolaas, J. Kwekkeboom, R.A. de Man, G. Kazemier, H.W. Tilanus, and et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age Liver Transpl 16 2010 837 846
349. J. Dantal, M. Hourmant, D. Cantarovich, M. Giral, G. Blancho, B. Dreno, and et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens Lancet 351 1998 623 628
350. J.O. O'Neill, L.B. Edwards, and D.O. Taylor Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation J Heart Lung Transplant 25 2006 1186 1191
351. C. Lebbe, S. Euvrard, B. Barrou, C. Pouteil-Noble, J.L. Garnier, D. Glotz, and et al. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma Am J Transplant 6 2006 2164 2168
352. R. Calne, P. Friend, S. Moffatt, A. Bradley, G. Hale, J. Firth, and et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients Lancet 351 1998 1701 1702
353. T.E. Starzl Acquired immunologic tolerance: with particular reference to transplantation Immunol Res 38 2007 6 41
354. T.E. Starzl Immunosuppressive therapy and tolerance of organ allografts N Engl J Med 358 2008 407 411
355. N. Assy, P.C. Adams, P. Myers, V. Simon, G.Y. Minuk, W. Wall, and et al. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid Transplantation 83 2007 1571 1576
356. J. Devlin, D. Doherty, L. Thomson, T. Wong, P. Donaldson, B. Portmann, and et al. Defining the outcome of immunosuppression withdrawal after liver transplantation Hepatology 27 1998 926 933
357. J.D. Eason, A.J. Cohen, S. Nair, T. Alcantera, and G.E. Loss Tolerance: is it worth the risk? Transplantation 79 2005 1157 1159
358. S. Feng, U.D. Ekong, S.J. Lobritto, A.J. Demetris, J.P. Roberts, P. Rosenthal, and et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants JAMA 307 2012 283 293
359. R. Girlanda, M. Rela, R. Williams, J.G. O'Grady, and N.D. Heaton Long-term outcome of immunosuppression withdrawal after liver transplantation Transplant Proc 37 2005 1708 1709
360. G.V. Mazariegos, J. Reyes, I.R. Marino, A.J. Demetris, B. Flynn, W. Irish, and et al. Weaning of immunosuppression in liver transplant recipients Transplantation 63 1997 243 249
361. F. Oike, A. Yokoi, E. Nishimura, Y. Ogura, Y. Fujimoto, M. Kasahara, and et al. Complete withdrawal of immunosuppression in living donor liver transplantation Transplant Proc 34 2002 1521
362. J.A. Pons, J. Yelamos, P. Ramirez, M. Oliver-Bonet, A. Sanchez, M. Rodriguez-Gago, and et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression Transplantation 75 2003 1045 1047
363. M. Takatsuki, S. Uemoto, Y. Inomata, H. Egawa, T. Kiuchi, S. Fujita, and et al. Weaning of immunosuppression in living donor liver transplant recipients Transplantation 72 2001 449 454
364. G. Tisone, G. Orlando, A. Cardillo, G. Palmieri, T.M. Manzia, L. Baiocchi, and et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence J Hepatol 44 2006 702 709
365. P. Tryphonopoulos, A.G. Tzakis, D. Weppler, R. Garcia-Morales, T. Kato, J.R. Madariaga, and et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation Am J Transplant 5 2005 608 613
366. G. Orlando, T. Manzia, L. Baiocchi, A. Sanchez-Fueyo, M. Angelico, and G. Tisone The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months Transpl Immunol 20 2008 43 47
367. J.A. Pons, P. Ramirez, B. Revilla-Nuin, D. Pascual, A. Baroja-Mazo, R. Robles, and et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients Clin Transplant 23 2009 329 336
368. M.C. Londono, A. Rimola, J. O'Grady, and A. Sanchez-Fueyo Immunosuppression minimization vs. complete drug withdrawal in liver transplantation J Hepatol 59 2013 872 879
369. C. Benitez, M.C. Londono, R. Miquel, T.M. Manzia, J.G. Abraldes, J.J. Lozano, and et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients Hepatology 58 2013 1824 1835
370. M. Garcia-Retortillo, X. Forns, A. Feliu, E. Moitinho, J. Costa, M. Navasa, and et al. Hepatitis C virus kinetics during and immediately after liver transplantation Hepatology 35 2002 680 687
371. L.M. Forman, J.D. Lewis, J.A. Berlin, H.I. Feldman, and M.R. Lucey The association between hepatitis C infection and survival after orthotopic liver transplantation Gastroenterology 122 2002 889 896
372. M. Berenguer, L. Ferrell, J. Watson, M. Prieto, M. Kim, M. Rayon, and et al. HCV-related fibrosis progression following liver transplantation: increase in recent years J Hepatol 32 2000 673 684
373. A. Blasco, X. Forns, J.A. Carrion, J.C. Garcia-Pagan, R. Gilabert, A. Rimola, and et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation Hepatology 43 2006 492 499
374. J.A. Carrion, F. Torres, G. Crespo, R. Miquel, J.C. Garcia-Valdecasas, M. Navasa, and et al. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation Hepatology 51 2010 23 34
375. G. Crespo, S. Lens, M. Gambato, J.A. Carrion, Z. Marino, M.C. Londono, and et al. Liver stiffness 1 year after transplantation predicts clinical outcomes in patients with recurrent hepatitis C Am J Transplant 14 2014 375 383
376. N.A. Terrault Hepatitis C therapy before and after liver transplantation Liver Transpl 14 2008 S58 S66
377. K.A. Brown, R.J. Fontana, M.W. Russo, J. Levitsky, E.M. Yoshida, H.E. Vargas, and et al. Twice-daily telaprevir in combination with peginterferon alfa-2a/ribavirin in genotype 1 HCV liver transplant recipients: interim week 16 safety and efficacy results of the prospective, multicenter REFRESH study Hepatology 58 2013 209A
378. A. Coilly, J. Dumortier, D. Botta-Fridlund, M. Latournerie, V. Leroy, G.P. Pageaux, and et al. Sustained virological response after protease inhibitorbased therapy for hepatitis C recurrence after liver transplantation: a multicentric european experience Hepatology 58 2013 316A
379. N. Faisal, E.L. Renner, M. Bilodeau, E.M. Yoshida, P. Wong, M.M. Ma, and et al. Protease inhibitor-based triple therapy is highly effective in liver transplant recipients with genotype 1 hepatitis C recurrence: a Canadian multicentre experience Hepatology 58 2013 238A
380. M. Gambato, S. Lens, M. Navasa, and X. Forns Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation J Hepatol 61 2014 S120 S131
381. A. Coilly, B. Roche, J.C. Duclos-Vallee, and D. Samuel Management of HCV transplant patients with triple therapy Liver Int 34 2014 46 52
382. M. Charlton, E. Gane, M.P. Manns, R.S. Brown Jr., M.P. Curry, P.Y. Kwo, and et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation Gastroenterology 148 2015 108 117
383. X. Forns, M. Charlton, J. Denning, J.G. McHutchison, W.T. Symonds, D. Brainard, and et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation Hepatology 61 2015 1485 1494
384. P.Y. Kwo, P.S. Mantry, E. Coakley, H.S. Te, H.E. Vargas, R.S. Brown Jr., and et al. An interferon-free antiviral regimen for HCV after liver transplantation N Engl J Med 371 2014 2375 2382
385. M. Charlton, G.T. Everson, S.L. Flamm, P. Kumar, C. Landis, R.S. Brown Jr., and et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease Gastroenterology 149 2015 649 659
386. D. Dieterich, B.R. Bacon, S.L. Flamm, K.V. Kowdley, S. Milligan, N. Tsai, and et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population Hepatology 60 2014 220A
387. R.S. Brown, K.R.J. Reddy, J.G. O'Leary, A. Kuo, G. Morelli, R.T. Stravitz, and et al. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study Hepatology 60 2014 1269A
388. M. Berenguer, A. Palau, V. Aguilera, J.M. Rayon, F.S. Juan, and M. Prieto Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation Am J Transplant 8 2008 679 687
389. J.A. Carrion, M. Navasa, M. Garcia-Retortillo, J.C. Garcia-Pagan, G. Crespo, M. Bruguera, and et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study Gastroenterology 132 2007 1746 1756
390. D. Samuel, R. Muller, G. Alexander, L. Fassati, B. Ducot, J.P. Benhamou, and et al. Liver transplantation in European patients with the hepatitis B surface antigen N Engl J Med 329 1993 1842 1847
391. D. Samuel Liver transplantation and hepatitis B virus infection: the situation seems to be under control, but the virus is still there J Hepatol 34 2001 943 945
392. E. Cholongitas, J. Goulis, E. Akriviadis, and G.V. Papatheodoridis Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review Liver Transpl 17 2011 1176 1190
393. J. Dumortier, P. Chevallier, J.Y. Scoazec, F. Berger, and O. Boillot Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results Am J Transplant 3 2003 999 1002
394. J.S. Markowitz, P. Martin, A.J. Conrad, J.F. Markmann, P. Seu, H. Yersiz, and et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin Hepatology 28 1998 585 589
395. R. Loomba, A.K. Rowley, R. Wesley, K.G. Smith, T.J. Liang, F. Pucino, and et al. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis Clin Gastroenterol Hepatol 6 2008 696 700
396. E.J. Gane, P.W. Angus, S. Strasser, D.H. Crawford, J. Ring, G.P. Jeffrey, and et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation Gastroenterology 132 2007 931 937
397. M. Buti, A. Mas, M. Prieto, F. Casafont, A. Gonzalez, M. Miras, and et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation J Hepatol 38 2003 811 817
398. J. Fung, S.C. Chan, C. Cheung, M.F. Yuen, K.S. Chok, W. Sharr, and et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B Am J Gastroenterol 108 2013 942 948
399. N. Terrault Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era? Am J Gastroenterol 108 2013 949 951
400. M.R. Lucey, D.E. Schaubel, M.K. Guidinger, S. Tome, and R.M. Merion Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit Hepatology 50 2009 400 406
401. S. Faure, A. Herrero, B. Jung, Y. Duny, J.P. Daures, T. Mura, and et al. Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication J Hepatol 57 2012 306 312
402. G.E. Vaillant A 60-year follow-up of alcoholic men Addiction 98 2003 1043 1051
403. A. DiMartini, C. Crone, and M.A. Dew Alcohol and substance use in liver transplant patients Clin Liver Dis 15 2011 727 751
404. A. DiMartini, M.A. Dew, D. Chaiffetz, M.G. Fitzgerald, M.E. Devera, and P. Fontes Early trajectories of depressive symptoms after liver transplantation for alcoholic liver disease predicts long-term survival Am J Transplant 11 2011 1287 1295
405. A. Cuadrado, E. Fabrega, F. Casafont, and F. Pons-Romero Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease Liver Transpl 11 2005 420 426
406. J.P. Rice, and M.R. Lucey Should length of sobriety be a major determinant in liver transplant selection? Curr Opin Organ Transplant 18 2013 259 264
407. J. Dumortier, O. Guillaud, M. Adham, C. Boucaud, B. Delafosse, Y. Bouffard, and et al. Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center Am J Gastroenterol 102 2007 1032 1041
408. P. Tandon, K.J. Goodman, M.M. Ma, W.W. Wong, A.L. Mason, G. Meeberg, and et al. A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation Am J Gastroenterol 104 2009 1700 1706
409. D.T. Patil, and L.M. Yerian Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation Liver Transpl 18 2012 1147 1153
410. K.D. Watt, and M.R. Charlton Metabolic syndrome and liver transplantation: a review and guide to management J Hepatol 53 2010 199 206
411. X. Wang, J. Li, D.R. Riaz, G. Shi, C. Liu, and Y. Dai Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis Clin Gastroenterol Hepatol 12 2014 394 402 e1
412. M. El-Masry, C.A. Puig, and S. Saab Recurrence of non-viral liver disease after orthotopic liver transplantation Liver Int 31 2011 291 302
413. I.W. Graziadei Recurrence of primary sclerosing cholangitis after liver transplantation Liver Transpl 8 2002 575 581
414. I.W. Graziadei Live donor liver transplantation for primary sclerosing cholangitis: is disease recurrence increased? Curr Opin Gastroenterol 27 2011 301 305
415. M.S. Matter, T. Decaens, J.B. Andersen, and S.S. Thorgeirsson Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends J Hepatol 60 2014 855 865
416. K. Chen, K. Man, H.J. Metselaar, H.L. Janssen, M.P. Peppelenbosch, and Q. Pan Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation Liver Transpl 20 2014 261 269
417. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, and et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
418. C. Sposito, L. Mariani, A. Germini, M. Flores Reyes, M. Bongini, G. Grossi, and et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study J Hepatol 59 2013 59 66
419. D.H. Yoon, B.Y. Ryoo, M.H. Ryu, S.G. Lee, S. Hwang, D.J. Suh, and et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation Jpn J Clin Oncol 40 2010 768 773
420. T.A. Gonwa, M.L. Mai, L.B. Melton, S.R. Hays, R.M. Goldstein, M.F. Levy, and et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment Transplantation 72 2001 1934 1939
421. T.A. Gonwa, M.A. McBride, K. Anderson, M.L. Mai, H. Wadei, and N. Ahsan Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 6 2006 2651 2659
422. M. Rodriguez-Peralvarez, G. Germani, T. Darius, J. Lerut, E. Tsochatzis, and A.K. Burroughs Reducing early exposure to calcineurin inhibitors: the key factor for a successful renal sparing strategy Am J Transplant 13 2013 239
423. J. Gavalda, E. Vidal, and C. Lumbreras Infection prevention in solid organ transplantation Enferm Infecc Microbiol Clin 30 2012 27 33
424. S. Karuthu, and E.A. Blumberg Common infections in kidney transplant recipients Clin J Am Soc Nephrol 7 2012 2058 2070
425. N. Safdar, A. Said, M.R. Lucey, S.J. Knechtle, A. D'Alessandro, A. Musat, and et al. Infected bilomas in liver transplant recipients: clinical features, optimal management, and risk factors for mortality Clin Infect Dis 39 2004 517 525
426. C.N. Kotton, D. Kumar, A.M. Caliendo, A. Asberg, S. Chou, L. Danziger-Isakov, and et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation Transplantation 96 2013 333 360
427. M.R. Lucey, N. Terrault, L. Ojo, J.E. Hay, J. Neuberger, E. Blumberg, and et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation Liver Transpl 19 2013 3 26
428. P. Burra, A. Buda, U. Livi, P. Rigotti, G. Zanus, F. Calabrese, and et al. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? Eur J Gastroenterol Hepatol 18 2006 1065 1070
429. U. Allen, and J. Preiksaitis Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients Am J Transplant 9 2009 S87 S96
430. N. Singh, M.M. Wagener, I.R. Marino, and T. Gayowski Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices Transplantation 73 2002 63 67
431. M. Osawa, Y. Ito, T. Hirai, R. Isozumi, S. Takakura, Y. Fujimoto, and et al. Risk factors for invasive aspergillosis in living donor liver transplant recipients Liver Transpl 13 2007 566 570
432. R. Patel, D. Portela, A.D. Badley, W.S. Harmsen, J.J. Larson-Keller, D.M. Ilstrup, and et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation Transplantation 62 1996 926 934
433. G.A. Eschenauer, S.W. Lam, and P.L. Carver Antifungal prophylaxis in liver transplant recipients Liver Transpl 15 2009 842 858
434. S.I. Martin, and J.A. Fishman Pneumocystis pneumonia in solid organ transplant recipients Am J Transplant 9 2009 S227 S233
435. J. Torre-Cisneros, A. Doblas, J.M. Aguado, R. San Juan, M. Blanes, M. Montejo, and et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort Clin Infect Dis 48 2009 1657 1665
436. P. Munoz, C. Rodriguez, and E. Bouza Mycobacterium tuberculosis infection in recipients of solid organ transplants Clin Infect Dis 40 2005 581 587
437. B.R. Yehia, and E.A. Blumberg Mycobacterium tuberculosis infection in liver transplantation Liver Transpl 16 2010 1129 1135
438. S. Madhwal, A. Atreja, M. Albeldawi, R. Lopez, A. Post, and M.A. Costa Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies Liver Transpl 18 2012 1140 1146
439. S. Desai, J.C. Hong, and S. Saab Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management Liver Int 30 2010 948 957
440. K.D. Watt, R.A. Pedersen, W.K. Kremers, J.K. Heimbach, W. Sanchez, and G.J. Gores Long-term probability of and mortality from de novo malignancy after liver transplantation Gastroenterology 137 2009 2010 2017
441. M.M. Guichelaar, J. Schmoll, M. Malinchoc, and J.E. Hay Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors Hepatology 46 2007 1198 1207
442. G. Millonig, I.W. Graziadei, D. Eichler, K.P. Pfeiffer, G. Finkenstedt, P. Muehllechner, and et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study Liver Transpl 11 2005 960 966
443. G. Leidig-Bruckner, S. Hosch, P. Dodidou, D. Ritschel, C. Conradt, C. Klose, and et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study Lancet 357 2001 342 347
444. A. Monegal, M. Navasa, N. Guanabens, P. Peris, F. Pons, M.J. Martinez de Osaba, and et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics Osteoporos Int 12 2001 484 492
445. A. Sethi, and R.T. Stravitz Review article: medical management of the liver transplant recipient - a primer for non-transplant doctors Aliment Pharmacol Ther 25 2007 229 245
446. E.A. Engels, R.M. Pfeiffer, J.F. Fraumeni Jr., B.L. Kasiske, A.K. Israni, J.J. Snyder, and et al. Spectrum of cancer risk among US solid organ transplant recipients JAMA 306 2011 1891 1901
447. A. Finkenstedt, I.W. Graziadei, W. Oberaigner, W. Hilbe, K. Nachbaur, W. Mark, and et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients Am J Transplant 9 2009 2355 2361
448. I. Penn Posttransplantation de novo tumors in liver allograft recipients Liver Transpl Surg 2 1996 52 59
449. S. Euvrard, J. Kanitakis, and A. Claudy Skin cancers after organ transplantation N Engl J Med 348 2003 1681 1691
450. J.I. Herrero, A. Espana, J. Quiroga, B. Sangro, F. Pardo, J. Alvarez-Cienfuegos, and et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors Liver Transpl 11 2005 1100 1106
451. E. Chak, and S. Saab Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review Liver Int 30 2010 1247 1258
452. J.I. Herrero, F. Pardo, D. D'Avola, F. Alegre, F. Rotellar, M. Inarrairaegui, and et al. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal Liver Transpl 17 2011 402 408
453. N. Chandok, and K.D. Watt Burden of de novo malignancy in the liver transplant recipient Liver Transpl 18 2012 1277 1289
454. M. Bergner Quality of life, health status, and clinical research Med Care 27 1989 S148 S156
455. I.B. Wilson, and P.D. Cleary Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes JAMA 273 1995 59 65
456. F. Kanwal, R.D. Hays, A.M. Kilbourne, G.S. Dulai, and I.M. Gralnek Are physician-derived disease severity indices associated with health-related quality of life in patients with end-stage liver disease? Am J Gastroenterol 99 2004 1726 1732
457. M.A. Testa, and D.C. Simonson Assesment of quality-of-life outcomes N Engl J Med 334 1996 835 840
458. C.L. Jay, Z. Butt, D.P. Ladner, A.I. Skaro, and M.M. Abecassis A review of quality of life instruments used in liver transplantation J Hepatol 51 2009 949 959
459. M.D. Bona, G. Rupolo, P. Ponton, R.M. Iemmolo, P. Boccagni, C. Destro, and et al. The effect of recurrence of HCV infection of life after liver transplantation Transpl Int 11 1998 S475 S479
460. M. De Bona, P. Ponton, M. Ermani, R.M. Iemmolo, A. Feltrin, P. Boccagni, and et al. The impact of liver disease and medical complications on quality of life and psychological distress before and after liver transplantation J Hepatol 33 2000 609 615
461. T. Cowling, L.W. Jennings, R.M. Goldstein, E.Q. Sanchez, S. Chinnakotla, G.B. Klintmalm, and et al. Societal reintegration after liver transplantation: findings in alcohol-related and non-alcohol-related transplant recipients Ann Surg 239 2004 93 98
462. K. Ruppert, S. Kuo, A. DiMartini, and V. Balan In a 12-year study, sustainability of quality of life benefits after liver transplantation varies with pretransplantation diagnosis Gastroenterology 139 2010 1619 1629 29 e1-e4
463. R. Desai, N.V. Jamieson, A.E. Gimson, C.J. Watson, P. Gibbs, J.A. Bradley, and et al. Quality of life up to 30 years following liver transplantation Liver Transpl 14 2008 1473 1479
464. P. Burra, E. De Martin, S. Gitto, and E. Villa Influence of age and gender before and after liver transplantation Liver Transpl 19 2013 122 134
465. T. Cowling, L.W. Jennings, R.M. Goldstein, E.Q. Sanchez, S. Chinnakotla, G.B. Klintmalm, and et al. Liver transplantation and health-related quality of life: scoring differences between men and women Liver Transpl 10 2004 88 96
466. B. Bunzel, and K. Laederach-Hofmann Solid organ transplantation: are there predictors for posttransplant noncompliance? A literature overview Transplantation 70 2000 711 716
467. H.P. McDonald, A.X. Garg, and R.B. Haynes Interventions to enhance patient adherence to medication prescriptions: scientific review JAMA 288 2002 2868 2879
468. L. Osterberg, and T. Blaschke Adherence to medication N Engl J Med 353 2005 487 497
469. M.A. Dew, A.F. DiMartini, Dabbs A. De Vito, L. Myaskovsky, J. Steel, M. Unruh, and et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation Transplantation 83 2007 858 873
470. J. Cramer, R. Rosenheck, G. Kirk, W. Krol, and J. Krystal Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes Value Health 6 2003 566 573
471. A. Rodriguez, M. Diaz, A. Colon, and E.A. Santiago-Delpin Psychosocial profile of noncompliant transplant patients Transplant Proc 23 1991 1807 1809
472. G. Germani, S. Lazzaro, F. Gnoato, M. Senzolo, V. Borella, G. Rupolo, and et al. Nonadherent behaviors after solid organ transplantation Transplant Proc 43 2011 318 323
473. P. Burra, G. Germani, F. Gnoato, S. Lazzaro, F.P. Russo, U. Cillo, and et al. Adherence in liver transplant recipients Liver Transpl 17 2011 760 770
474. P. Burra The adolescent and liver transplantation J Hepatol 56 2012 714 722
475. S. Gilmour, R. Adkins, G.A. Liddell, G. Jhangri, and C.M. Robertson Assessment of psychoeducational outcomes after pediatric liver transplant Am J Transplant 9 2009 294 300
476. L.G. Sorensen, K. Neighbors, K. Martz, F. Zelko, J.C. Bucuvalas, and E.M. Alonso Cognitive and academic outcomes after pediatric liver transplantation: Functional Outcomes Group (FOG) results Am J Transplant 11 2011 303 311
477. E.M. Fredericks, J.C. Magee, L. Opipari-Arrigan, V. Shieck, A. Well, and M.J. Lopez Adherence and health-related quality of life in adolescent liver transplant recipients Pediatr Transplant 12 2008 289 299
478. S.M. Gilmour, L.G. Sorensen, R. Anand, W. Yin, and E.M. Alonso School outcomes in children registered in the studies for pediatric liver transplant (SPLIT) consortium Liver Transpl 16 2010 1041 1048
479. E. Shemesh Beyond graft survival and into the classroom: should school performance become a new posttransplant outcome measure? Liver Transpl 16 2010 1013 1015
480. H. Bownik, and S. Saab Health-related quality of life after liver transplantation for adult recipients Liver Transpl 15 2009 S42 S49
481. F. Aberg, K. Hockerstedt, R.P. Roine, H. Sintonen, and H. Isoniemi Influence of liver-disease etiology on long-term quality of life and employment after liver transplantation Clin Transplant 26 2012 729 735
482. A. Huda, R. Newcomer, C. Harrington, M.G. Blegen, and E.B. Keeffe High rate of unemployment after liver transplantation: analysis of the United Network for Organ Sharing database Liver Transpl 18 2012 89 99
483. P. Burra, G. Germani, A. Masier, E. De Martin, M. Gambato, A. Salonia, and et al. Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure? Transplantation 89 2010 1425 1429
484. D.M. Bravata, I. Olkin, A.E. Barnato, E.B. Keeffe, and D.K. Owens Health-related quality of life after liver transplantation: a meta-analysis Liver Transpl Surg 5 1999 318 331
485. J.K. Ho, H.H. Ko, D.F. Schaeffer, S.R. Erb, C. Wong, A.K. Buczkowski, and et al. Sexual health after orthotopic liver transplantation Liver Transpl 12 2006 1478 1484
486. J.H. Sorrell, and J.R. Brown Sexual functioning in patients with end-stage liver disease before and after transplantation Liver Transpl 12 2006 1473 1477
487. E. Huyghe, N. Kamar, F. Wagner, S.J. Yeung, A.H. Capietto, L. El-Kahwaji, and et al. Erectile dysfunction in liver transplant patients Am J Transplant 8 2008 2580 2589
488. P. Burra Sexual dysfunction after liver transplantation Liver Transpl 15 2009 S50 S56
489. E.M. Johnson, J. Zimmerman, K. Duderstadt, J. Chambers, A.L. Sorenson, D.K. Granger, and et al. A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients Transplant Proc 28 1996 987
490. S. Lee, M. Coco, S.M. Greenstein, R.S. Schechner, V.A. Tellis, and D.G. Glicklich The effect of sirolimus on sex hormone levels of male renal transplant recipients Clin Transplant 19 2005 162 167
491. K. Mass, E.H. Quint, M.R. Punch, and R.M. Merion Gynecological and reproductive function after liver transplantation Transplantation 62 1996 476 479
492. D.B. McKay, M.A. Josephson, V.T. Armenti, P. August, L.A. Coscia, C.L. Davis, and et al. Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation Am J Transplant 5 2005 1592 1599
493. L.R. Robinson, J. Switala, R.E. Tarter, and J.J. Nicholas Functional outcome after liver transplantation: a preliminary report Arch Phys Med Rehabil 71 1990 426 427
494. N. Beyer, M. Aadahl, B. Strange, P. Kirkegaard, B.A. Hansen, T. Mohr, and et al. Improved physical performance after orthotopic liver transplantation Liver Transpl Surg 5 1999 301 309
495. J.B. Krasnoff, A.Q. Vintro, N.L. Ascher, N.M. Bass, S.M. Paul, M.J. Dodd, and et al. A randomized trial of exercise and dietary counseling after liver transplantation Am J Transplant 6 2006 1896 1905
496. P. Painter, J. Krasnoff, S.M. Paul, and N.L. Ascher Physical activity and health-related quality of life in liver transplant recipients Liver Transpl 7 2001 213 219
497. A.E. Roske, and M. Plauth Liver transplantation, body composition, and substrate utilization: does organ transplantation normalize the metabolic situation of the patient? Nutrition 15 1999 504 505
498. E.R. Kallwitz Metabolic syndrome after liver transplantation: preventable illness or common consequence? World J Gastroenterol 18 2012 3627 3634
499. M. Didsbury, R.G. McGee, A. Tong, J.C. Craig, J.R. Chapman, S. Chadban, and et al. Exercise training in solid organ transplant recipients: a systematic review and meta-analysis Transplantation 95 2013 679 687
500. J. Richards, B. Gunson, J. Johnson, and J. Neuberger Weight gain and obesity after liver transplantation Transpl Int 18 2005 461 466
501. J.A. Fishman, and P.A. Grossi Donor-derived infection-the challenge for transplant safety Nat Rev Nephrol 10 2014 663 672